Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: A case report with in vitro studies

Hormone Research

Volumn 53, Issue 1, 2000, Pages 46-50

  Koriyama, Nobuyuki ^a   Kakei, Masafumi ^a   Yaekura, Kazuro ^a   Okui, Hideki ^a   Yamashita, Tsuminori ^a   Nishimura, Hiroaki ^a   Matsushita, Shinji ^a   Tei, Chuwa ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Catecholamine; Octreotide; Pheochromocytoma; Voltage dependent Ca2+ channel

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ADRENALIN; ALDOSTERONE; CALCIUM CHANNEL; CATECHOLAMINE; DOPAMINE; DOXAZOSIN MESYLATE; HOMOVANILLIC ACID; METADRENALIN; NORADRENALIN; OCTREOTIDE; RENIN; VANILMANDELIC ACID;

AGED; ARTICLE; BLOOD PRESSURE; CANCER SURGERY; CASE REPORT; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE RELEASE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; MALE; PATCH CLAMP; PHEOCHROMOCYTOMA; PRIORITY JOURNAL;

EID: 0033803005     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000023513     Document Type: Article

References (12)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-79.
2. Reichlin S: Somatostatin. N Engl J Med 1983; 309:1495-1501.
3. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J. Clin Invest 1994;93:1321-1325.
4. Wynick D, Bloom SR: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991;73:1-3.
5. Invitti C, De Martin J, Bolla GB, Pecori Giraldi F, Maestri E, Leonetti G, Cavagnini F: Effect of octreotidc on catecholamine plasma levels in patients with chromaffin cell tumors. Horm Res 1993;40:156-160.
6. Kakei M, Nakazaki M, Kamisaki T, Nagayama I, Fukamachi Y, Tanaka H: Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic β-cells. Br J Pharmacol 1993;109:1226-1231.
7. 2+ currents by acetylcholine in mouse pancreatic β-cells. J Physiol (Lond) 1997;499:65-76.
8. Baxter MA, Hunter P, Thompson GR, London DR: Phaeochromocytomas as a cause of hypotension. Clin Endocrinol 1992;37:304-306.
9. Perry RR, Keiser HR, Norton JA, Wall RT, Robertson CN, Travis W, Pass HI, Walther MM, Linehan WM: Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg 1990;212:621-628.
10. Plouin PF, Bertherat J, Chateiller G, Billaud E, Azizi M, Grouzmann E, Epeibaum J: Short-term effects of octreotidc on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial. Clin Endocrinol 1995; 42:289-294.
11. Maynard KI, Saville VL, Burnstock G: Somatostatin modulates vascular sympathetic neurotransmission in the rabbit car artery. Eur J Pharmacol 1991;196:125-131.
12. Fujii Y, Gonoi T, Yamada Y, Chihara K, Inagaki N, Seino S: Somatostatin receptor subtype SSTR2 mediates the inhibition of high-voltage-activated calcium channels by somatostatin and its analogue SMS 201-995. FEBS Lett 1994;355:117-120.